Pont

The Centre national des arts plastiques launches a call for application for a commissioned artwork in memory of the genocide against the Tutsi of Rwanda

Retrieved on: 
Monday, June 26, 2023
Pont de l'Alma, Pont des Invalides, Memory, Museum, Pont

The artwork will be permanently placed on the esplanade between the Pont de l'Alma and the Pont des Invalides bridges, in the 7th arrondissement of Paris, jointly visible with several historic monuments.

Key Points: 
  • The artwork will be permanently placed on the esplanade between the Pont de l'Alma and the Pont des Invalides bridges, in the 7th arrondissement of Paris, jointly visible with several historic monuments.
  • Led by the Centre national des arts plastiques (Cnap), this international call for application will allow for the selection of the artist commissioned to design and create this work of art.
  • The steering and selection committee will gather a second time in January 2024 to choose the project to be pursued.
  • The chosen artist could be presented to the public during the genocide's 30th annual commemoration.

The Centre national des arts plastiques launches a call for application for a commissioned artwork in memory of the genocide against the Tutsi of Rwanda

Retrieved on: 
Monday, June 26, 2023
Pont de l'Alma, Pont des Invalides, Memory, Museum, Pont

The artwork will be permanently placed on the esplanade between the Pont de l'Alma and the Pont des Invalides bridges, in the 7th arrondissement of Paris, jointly visible with several historic monuments.

Key Points: 
  • The artwork will be permanently placed on the esplanade between the Pont de l'Alma and the Pont des Invalides bridges, in the 7th arrondissement of Paris, jointly visible with several historic monuments.
  • Led by the Centre national des arts plastiques (Cnap), this international call for application will allow for the selection of the artist commissioned to design and create this work of art.
  • The steering and selection committee will gather a second time in January 2024 to choose the project to be pursued.
  • The chosen artist could be presented to the public during the genocide's 30th annual commemoration.

Avirmax Biopharma Inc. Will Present at Glaucoma 360 New Horizons Forum 2023

Retrieved on: 
Friday, February 3, 2023
Rat, Detection, DARC, Excitotoxicity, Mouse, Therapy, Glaucoma, Westin St. Francis, Rita Raave, ABI, NMDA, Patient, Chief scientific officer, CMC, Research, IOP, Death, FDA, RGC, Paratriathlon, Pont, Pharmaceutical industry

HAYWARD, Calif., Feb. 3, 2023 /PRNewswire/ -- Avirmax Biopharma Inc. (ABI), Chief Executive and Scientific Officer, Shengjiang Shawn Liu will present the Avirmax BioPharma Inc (ABI)'s progress in the innovation and development of genetic medicines for glaucoma treatment at Glaucoma 360 New Horizons Forum at The Westin St. Francis in San Francisco, Feb 03, 2023.

Key Points: 
  • HAYWARD, Calif., Feb. 3, 2023 /PRNewswire/ -- Avirmax Biopharma Inc. (ABI), Chief Executive and Scientific Officer, Shengjiang Shawn Liu will present the Avirmax BioPharma Inc (ABI)'s progress in the innovation and development of genetic medicines for glaucoma treatment at Glaucoma 360 New Horizons Forum at The Westin St. Francis in San Francisco, Feb 03, 2023.
  • Since its founding, Avirmax Biopharma Inc (ABI) has been focusing on developing an effective gene therapy product, ABI-902 for glaucoma treatment.
  • ABI-902 is manufactured by Avirmax CMC Inc.
    Now in its 12th year, the Glaucoma 360 New Horizons Forum unites key clinical, industrial, financial, and FDA leaders in a unique exchange on research innovation and advances in glaucoma treatment.
  • Avirmax Biopharma Inc. (ABI) is a subsidiary of Avirmax Inc., a San Francisco Bay Area based company working on genetic medicine.

Two Tech Industry Leaders Team Up to Produce Super-Drone Solution

Retrieved on: 
Tuesday, January 18, 2022
Fire, Aviation, Plan, Police, Unmanned aerial vehicle, Person, Law enforcement, MRO, Emergency, AFRL, Comprehension, Emergency medical technician, OH, Firefighter, Partnership, MMC, CEO, Radio, Smoke, Communication, UAS, Solution, GPS, Software, Survivor, AD, Crime, Veteran, School, ArcGIS, Time, Software as a service, Wildfire, Risk, Military personnel, AWARE, Darkness, Hospital, Pont, Risk management, Mobile phone, Private investigator, Beekeeping, Collaboration, Spartacus

The longer it takes to assess a dangerous situation and deploy the appropriate action, the greater the chance of the incident escalating.

Key Points: 
  • The longer it takes to assess a dangerous situation and deploy the appropriate action, the greater the chance of the incident escalating.
  • "Additionally, Aquiline Drones' maintenance repair overhaul (MRO) model guarantees fully functional operational UAVs, which eliminates worry and ensures high quality use when it matters most."
  • Team members can rapidly and easily send and receive secure messages, pictures, and video while also following along with MMC transcription.
  • AD's full spectrum of technological solutions is widely applicable across countless industries and environments for superior, real-time data processing and insights.

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In The Chemours Company To Contact The Firm

Retrieved on: 
Friday, October 18, 2019
Humans, Companies, DuPont, Whistleblower, DuPont, Pierre Samuel du Pont de Nemours, Pont, Human rights

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to [email protected].

Key Points: 
  • You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to [email protected].
  • du Pont de Nemours and Company ("DuPont") which began trading as its own public company in 2015.
  • Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Chemours's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.